Table 2.
Treatment-related adverse events
| Event | All patients (N=48, 100%) | |
| Any grade | Grade≥3 | |
| Any TRAE | 44 (91.7%) | 4 (8.3%) |
| Pruritus | 7 (14.6%) | 0 |
| Increased AST or ALT | 4 (8.3%) | 2 (4.2%) |
| Skin rash | 4 (8.3%) | 0 |
| Hypothyroidism | 4 (8.3%) | 0 |
| Fatigue | 4 (8.3%) | 0 |
| Increased ALP or GGT | 3 (6.3%) | 1 (2.1%) |
| Hyperbilirubinemia | 2 (4.2%) | 0 |
| Nausea | 2 (4.2%) | 0 |
| Dizziness | 2 (4.2%) | 0 |
| Adrenal insufficiency | 2 (4.2%) | 0 |
| Myalgia | 2 (4.2%) | 0 |
| Itching sense | 2 (4.2%) | 0 |
| Sore throat | 1 (2.1%) | 0 |
| Hyperglycemia | 1 (2.1%) | 0 |
| Pneumonitis | 1 (2.1%) | 0 |
| Acute kidney injury | 1 (2.1%) | 1 (2.1%) |
| Arthralgia | 1 (2.1%) | 0 |
| Chills | 1 (2.1%) | 0 |
| Conjunctivitis | 1 (2.1%) | 0 |
| Abdominal pain | 1 (2.1%) | 0 |
| Dry mouth | 1 (2.1%) | 0 |
| Eosinophilia | 1 (2.1%) | 0 |
| Gait disturbance | 1 (2.1%) | 0 |
| Peripheral neuropathy | 1 (2.1%) | 0 |
| Thrombocytopenia | 1 (2.1%) | 0 |
| Hypoalbuminemia | 1 (2.1%) | 0 |
| Hypocalcemia | 1 (2.1%) | 0 |
| Hypokalemia | 1 (2.1%) | 0 |
| Abdominal pain | 1 (2.1%) | 0 |
| Palmar-plantar erythrodysesthesia syndrome | 1 (2.1%) | 0 |
| Shingles | 1 (2.1%) | 0 |
| Upper respiratory infection | 1 (2.1%) | 0 |
| Vomiting | 1 (2.1%) | 0 |
| Wound infection | 1 (2.1%) | 0 |
ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase; TRAE, treatment-related adverse event.